drugset / Trial / NCT00928525

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

NCT00928525 ↗

Phase 2 Completed 35 enrolled Italian Sarcoma Group
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta

Timeline

Start
2007-05
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg Oral